Pembrolizumab-Induced Smoldering Myocarditis in Patients With Triple-Negative Breast Cancer
Immune checkpoint inhibitors (ICI), in combination with chemotherapy, have been approved for the treatment of triple-negative breast cancer (TNBC). ICI-induced myocarditis is a rare complication with a high mortality rate. Diagnosis of ICI-induced myocarditis can be challenging because of the heterogeneity of clinical presentation, histopathological studies, and severity of disease. Smoldering myocarditis is a subclinical myocarditis in which patients are asymptomatic or present with mild, nonspecific signs and symptoms. To date, there have been no reports on the incidence, characteristics, or outcomes of ICI-induced SM in TNBC. Herein, we highlight 2 cases of pembrolizumab-induced smoldering myocarditis in patients treated with ICI for TNBC.
Authors
- Adam S. Potter (ORCID: https://orcid.org/0000-0002-1839-8008)
- Margaret E. Gatti‐Mays (ORCID: https://orcid.org/0000-0001-8914-2897)
- Nicole Williams (ORCID: https://orcid.org/0000-0002-0339-1612)
- Alexa Meara (ORCID: https://orcid.org/0000-0002-8406-3556)
- Adnan Shaaban (ORCID: https://orcid.org/0000-0002-0036-7297)
- Dionisia Quiroga (ORCID: https://orcid.org/0000-0003-3388-7069)
- Sagar Sardesai (ORCID: https://orcid.org/0000-0002-2688-0486)
- Daniel Addison (ORCID: https://orcid.org/0000-0002-9113-8333)
- Mathew Cherian (ORCID: https://orcid.org/0000-0001-5843-3886)
- Kara N. Corps (ORCID: https://orcid.org/0000-0002-5584-6738)
- Gilbert Bader (ORCID: https://orcid.org/0000-0003-3576-7693)
- Kai Johnson (ORCID: https://orcid.org/0000-0002-5779-4732)
- Ashley Pariser Davenport (ORCID: https://orcid.org/0000-0002-7993-6316)
- Daniel G. Stover
- Robert Wesolowski
- Alma Habib (ORCID: https://orcid.org/0000-0003-4429-3602)
Institutions
- The Ohio State University Wexner Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1016/j.jaccas.2025.103271
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05